What prescribing practices trigger GMC referral, how investigations work, controlled drug concerns, self-prescribing, and how to demonstrate remediation
Prescribing concerns are one of the most common sources of GMC fitness to practise referrals. They range from clinical errors to controlled drug fraud — and the regulatory consequences vary accordingly. This guide explains what triggers a GMC prescribing investigation, how it proceeds, and what remediation evidence makes the difference.
Prescribing is one of the most regulated aspects of medical practice — and one of the most common sources of GMC fitness to practise concerns.
GMC Good Medical Practice sets out clear expectations: prescribing must be based on adequate clinical assessment, must be in the patient's best interests, and must comply with legal requirements and relevant clinical guidelines.
Prescribing concerns that reach the GMC span a wide range — from isolated clinical errors at one end to deliberate prescription fraud at the other. The regulatory response depends heavily on whether the concern is primarily a clinical competence issue or whether it involves dishonesty, self-interest, or an abuse of the prescribing privilege.
Common prescribing practices that raise GMC concerns include inadequate clinical assessment before prescribing, failure to review repeat prescriptions, prescribing outside the doctor's competence, issuing prescriptions without seeing the patient, and departing from established clinical guidelines without documented clinical justification.
CPD Certified — Online — Immediate Access
Controlled drug prescribing attracts the most intensive scrutiny in GMC prescribing investigations. The regulatory framework for controlled drugs is strict — and departures from it raise concerns that go beyond clinical competence into the territory of probity and patient safety.
GMC concerns about controlled drug prescribing most commonly arise from:
Where controlled drug concerns overlap with dishonesty, the investigation moves from the clinical performance stream into the conduct stream — with correspondingly more serious potential consequences.
Repeat prescribing without adequate clinical oversight is a persistent source of GMC concerns. It is most commonly seen in primary care, where high prescription volumes and time pressures can lead to prescriptions being issued without recent clinical review of the patient's ongoing need.
The GMC expects doctors to have systems in place to ensure repeat prescriptions are reviewed regularly, that clinical indications remain current, and that patients on long-term medications are seen at appropriate intervals.
Failure to maintain these systems — particularly where patient harm results — is treated as a clinical governance failure that can constitute impaired fitness to practise.
In cases where repeat prescribing has caused patient harm, the clinical competence and patient safety dimension of the case is assessed alongside the prescribing concern itself.
The two are not separable — prescribing decisions are clinical decisions and are assessed as such.
Prescribing to oneself, to family members, or to close personal associates is treated by the GMC as a serious concern. GMC Good Medical Practice is explicit: doctors should not prescribe for themselves or anyone with whom they have a close personal relationship, except in genuine emergencies where no other doctor is available.
The reasons are straightforward. Self-prescribing undermines the objectivity of clinical decision-making.
Prescribing for family members or associates removes the professional distance that good prescribing requires. Both practices risk inappropriate prescribing — and in the case of controlled drugs, they raise additional concerns about misuse and diversion.
Where self-prescribing involves controlled drugs, the concern is particularly acute. It can engage the GMC health pathway if substance misuse is involved, or the conduct stream if the prescribing is viewed as dishonest or an abuse of prescribing authority.
See the broader guide to the GMC health pathway for context on health-related prescribing concerns.
A GMC prescribing investigation follows the standard fitness to practise process but involves detailed scrutiny of prescribing records. The GMC has powers to obtain prescribing data from NHS systems, dispensing records from pharmacies, and clinical notes from the relevant period.
The investigation typically involves:
Remediation in a prescribing case must address the specific concern raised. Generic CPD in professional ethics, while valuable, is not sufficient on its own — the remediation evidence must show that the doctor has engaged specifically with prescribing standards and practice.
What a strong prescribing remediation file looks like:
Completing courses early — during the investigation period rather than immediately before any hearing — demonstrates that the engagement with prescribing standards is genuine rather than reactive.
For overseas-qualified doctors, GMC prescribing findings may be shared with regulatory bodies in home jurisdictions.
UK-registered doctors can access professional ethics training through Healthcare Ethics Courses.
Doctors with connections to Australia can consult ethics training for Australian doctors.
Those with connections to the USA can review professional development for US doctors.
10 CPD-certified courses for £500. Targeted prescribing CPD, professional ethics, and reflective practice — completed during the investigation, not the week before the hearing.
Bulk Buy 10 Courses →Inadequate clinical assessment before prescribing, failure to review repeat prescriptions, prescribing outside competence, controlled drug concerns including excessive volumes and diversion, self-prescribing, prescribing for family or associates, and prescription fraud. The GMC receives prescribing concerns from NHS bodies, pharmacies, employers, and patients.
Not illegal in the strict sense but a serious breach of Good Medical Practice. The GMC expects doctors not to prescribe for themselves or close personal associates except in genuine emergencies. Self-prescribing of controlled drugs is treated as a particularly serious concern and can engage both the conduct and health pathways.
The GMC obtains prescribing records, controlled drug registers, pharmacy dispensing data, and clinical notes. An independent clinical expert reviews the prescribing against relevant guidelines. The concern may be treated as a clinical performance issue, a conduct/probity issue, or both — depending on whether dishonesty or misuse is alleged.
Yes. Where prescribing concerns involve deliberate fraud, dishonesty, or serious patient harm, erasure is possible. Clinical performance concerns without dishonesty are more likely to result in conditions, undertakings, or suspension — but serious cases can result in the full range of sanctions.
Doctors must have systems to ensure repeat prescriptions are reviewed regularly, clinical indications remain current, and patients on long-term medications are seen at appropriate intervals. Issuing repeat prescriptions without adequate clinical oversight — particularly where harm results — is a clinical governance failure that can impair fitness to practise.
By appointing an independent clinical expert who reviews the prescribing records and clinical notes against the relevant guidelines — including NICE guidance, BNF, controlled drug regulations, and local formularies. Departures from guidelines must be clinically justified and documented.
Targeted CPD in safe prescribing and the relevant clinical area, a specific reflective statement addressing the prescribing concern, documented practice changes including new review protocols, a prescribing audit showing current practice meets standards, and a supervisor report where available.
Yes. Where the prescribing concern is primarily clinical rather than involving dishonesty, and where the doctor has taken genuine remediation steps, an agreed outcome — undertakings or conditions — is possible. This is more likely where the concern was isolated and the doctor has demonstrated insight and practice change.
Courses specifically addressing safe prescribing, controlled drug regulations, clinical governance in prescribing, and the relevant clinical area. Generic ethics CPD should accompany — not replace — prescribing-specific training. Complete courses during the investigation period, not as a last-minute addition before a hearing.
A prescribing audit reviews a defined sample of prescriptions against specified criteria — usually the relevant clinical guidelines and regulatory requirements. In a GMC prescribing case, an audit demonstrating that current practice meets standards provides independent, documented evidence that the prescribing concern has been addressed.
The GMC's standards apply equally. However, the context differs — GP prescribing investigations often involve high-volume repeat prescribing, while hospital prescribing concerns more often involve specialist medication decisions. The investigation approach and expert assessment are tailored to the clinical context.
Contact your medical defence organisation immediately. Do not respond to the GMC until you have taken advice. Gather your prescribing records and clinical notes for the relevant period. Begin targeted CPD in the relevant prescribing area. Obtain specialist legal advice if the concern involves controlled drugs or allegations of dishonesty.
Yes. Where a prescribing concern involves self-prescribing of controlled drugs or where substance misuse is alleged, the health pathway and conduct stream can run in parallel. The GMC will assess both dimensions. Engaging proactively with health support — including the Practitioner Health Programme — is strongly advisable.
This guide is for educational purposes only and does not constitute legal advice. If you are facing a GMC prescribing investigation, seek independent legal advice from a solicitor experienced in GMC regulatory proceedings.
